Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015634
Filing Date
2024-11-14
Accepted
2024-11-14 09:30:02
Documents
71
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q pmn-20240930x10q.htm   iXBRL 10-Q 1834704
2 EX-31.1 pmn-20240930xex31d1.htm EX-31.1 9063
3 EX-31.2 pmn-20240930xex31d2.htm EX-31.2 8963
4 EX-32.1 pmn-20240930xex32d1.htm EX-32.1 10759
  Complete submission text file 0001558370-24-015634.txt   7386935

Data Files

Seq Description Document Type Size
5 EX-101.SCH pmn-20240930.xsd EX-101.SCH 60621
6 EX-101.CAL pmn-20240930_cal.xml EX-101.CAL 39606
7 EX-101.DEF pmn-20240930_def.xml EX-101.DEF 191585
8 EX-101.LAB pmn-20240930_lab.xml EX-101.LAB 464388
9 EX-101.PRE pmn-20240930_pre.xml EX-101.PRE 342546
74 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20240930x10q_htm.xml XML 1254759
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41429 | Film No.: 241457782
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)